23andMe Review 2026: What to Know After the Bankruptcy

23andMe is the test that put consumer genetics on the map, and it is also the test we currently have the most caveats about. The company filed for Chapter 11 bankruptcy in March 2025. Its genetic data and core consumer assets were sold to TTAM Research Institute, a nonprofit founded by co-founder Anne Wojcicki, in mid-2025. A wind-down plan was approved in late 2025. The consumer test still ships and the website still works, but the corporate and privacy picture is materially different than it was two years ago.

This review covers what 23andMe actually delivers as a product, where it still leads, and what the post-bankruptcy situation means for buyers as of early 2026.

At a glance

• Base price: roughly $99 for the Ancestry service historically; the Health + Ancestry tier has typically started around $199. Verify current pricing on the live site, which is in flux post-bankruptcy.
• Turnaround: 3 to 5 weeks
• Database size: approximately 14 million profiles, reportedly down from roughly 15 million after the 2023 breach and subsequent attrition
• Health reporting: yes, including FDA-authorized carrier status and certain genetic health risk reports
• Accepts raw data uploads from other tests: no
• Status: active but unstable. We mark this product “verify” until the post-TTAM situation stabilizes.

Who this test is for

23andMe is for buyers who specifically want combined ancestry and health reporting from a single product, are comfortable with the corporate situation described below, and have read our genetic data privacy coverage first.

It is also the only major consumer test with FDA-authorized direct-to-consumer health reports, including carrier status reports and a handful of genetic health risk reports. The FDA’s authorization pages document what those reports are cleared to say (see the FDA’s record of De Novo classifications for 23andMe’s Personal Genome Service Genetic Health Risk reports). The authorizations cover the analytical and clinical validity of specific named variants, not a general health prediction.

Who should look elsewhere

If you want the largest possible ancestry matching pool, AncestryDNA is the stronger choice on database size alone.

If the post-bankruptcy uncertainty is a deal-breaker, MyHeritage and FamilyTreeDNA accept free uploads of 23andMe raw data, so you can move your data elsewhere later, but you cannot use those services for the FDA-authorized health reports.

If you want health interpretation done by a professional rather than a report you read alone, talk to a genetic counselor before testing, not after. The NSGC Find a Genetic Counselor directory lets you search by location and specialty.

What you get for your money

The kit is a saliva collection tube with a stabilizing buffer and a prepaid return mailer. You spit, register the kit code online, and post it back. Within 3 to 5 weeks of the lab receiving the sample, you get access to ancestry composition (ethnicity percentages and a chromosome painting), DNA Relatives matching, maternal and paternal haplogroup reports, and (on the Health + Ancestry tier) the health report library.

The health reports include carrier status reports for conditions such as cystic fibrosis and sickle cell anemia, genetic health risk reports for a defined set of conditions (including the three founder BRCA1/BRCA2 variants most common in people of Ashkenazi Jewish descent), wellness reports, and a pharmacogenetics report. Each FDA-authorized report covers specific named variants. It does not screen every relevant variant in a given gene, which is a non-trivial limitation that we’ll come back to.

How accurate is it?

The underlying genotyping is highly accurate at the SNPs 23andMe tests, and the FDA-authorized reports have been reviewed for analytical and clinical validity of the specific variants they cover. That is a meaningful regulatory bar that no competitor has cleared at the same breadth.

The catch sits inside the word “specific.” The BRCA1/BRCA2 report, for example, covers three variants most common in Ashkenazi Jewish populations out of more than a thousand variants known to be associated with hereditary breast and ovarian cancer. A “variants not detected” result from 23andMe is not a clinical negative. The FDA’s authorization documentation says this directly. We mention it because it is the single most-misunderstood thing about consumer health DNA testing.

Ethnicity estimates are accurate within the usual fuzziness of the category and update periodically.

Strengths

Combined ancestry and health under one product, an established health report library, and FDA authorization for the carrier and genetic health risk categories. Strong UI for haplogroup and trait exploration.

Limitations

Smaller match database than AncestryDNA, roughly half the size. Does not accept raw data uploads. Health reports cover specific variants only and must not be read as comprehensive screening. No Y-DNA or mtDNA sequencing; the haplogroup assignment is derived from the autosomal genotyping array.

Privacy notes

This is where 23andMe currently demands more reading than any other test. In October 2023, attackers used credential stuffing to access 23andMe accounts and, via the DNA Relatives feature, scraped data linked to roughly 6.9 million users (per 23andMe’s own disclosures). The company later faced class-action litigation and regulatory action over the breach.

In March 2025, 23andMe filed for Chapter 11 bankruptcy. The genetic data and core consumer assets were sold to TTAM Research Institute, a nonprofit founded by Anne Wojcicki, in mid-2025. The wind-down plan was approved in late 2025. As of early 2026, the consumer service still operates under the post-sale entity, but the long-term ownership and data governance picture is different from what existing customers signed up for.

We are not telling you not to buy the test. We are telling you to read our genetic data privacy coverage first, decide how you feel about the post-TTAM data steward, and consider downloading your raw data shortly after results arrive in case you later want to delete your account.

Verdict

If you specifically want FDA-authorized health reports plus ancestry from a single test and you have read the privacy section above, 23andMe is still the option that exists. If you mainly care about ancestry, buy AncestryDNA instead. If you want a professional to interpret a health-relevant genetic finding, talk to a genetic counselor before or after, not instead of, reading any report.

Where to buy: 23andMe

Related reading: DNA test accuracy explained, raw DNA data explained, best DNA test for health, what to do after DNA test results. Back to the guide to DNA testing pillar.